A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

A Randomized, Open-label Study of the Effect of Omnitarg in Combination With Carboplatin-based Chemotherapy Versus Carboplatin-based Therapy Alone on Treatment Response in Patients With Platinum-sensitive Recurrent Ovarian Cancer

This study will evaluate the efficacy and safety of pertuzumab in combination with carboplatin-based standard chemotherapy in patients with platinum-sensitive recurrent ovarian cancer. The anticipated time on study treatment is 3-12 months.

Inclusion Criteria:

• histologically confirmed ovarian, primary peritoneal, or fallopian tube cancer;
• only 1 previous regimen, which must be platinum-based;
• platinum-sensitive disease which is defined by a progression-free interval of greater than 6 months after completion of platinum-based chemotherapy.

Exclusion Criteria:

• previous radiotherapy;
• previous treatment with an anti-cancer vaccine or any targeted therapy;
• major surgery or traumatic injury within 4 weeks of study;
• history or evidence of central nervous system metastases.